Germán-Garrido CO, Campos-Salcedo JG, Zapata-Villalba MÁ, López-Silvestre JC, Mendoza-Álvarez LA, Estrada-Carrasco LA

Language: Spanish
References: 12
Page: 346-352
PDF size: 332.90 Kb.

ABSTRACT

Background:Testicular cancer is the most common solid tumor in men between 15 and 35 years of age. It represents 1% of all cancers in males, with a 0.2% lifetime risk for developing the disease.
Aims: To examine and describe the epidemiology and oncologic progression of testicular tumor in patients treated at our hospital.
Materials and Methods: An ambispective study was conducted on patients seen at the Hospital Militar Central within the time frame of January 2006 and October 2016. We conducted a retrospective analysis of the risk factors, tumor markers, tumor stage, international risk group classification, and treatment modality. The outcomes evaluated were recurrence-free survival and overall survival.
Results: The study included 115 patients. The most common histologic strain was seminoma (53.4%) and in the nonseminomatous tumors it was embryonal carcinoma. A total of 10.4% of the cases had a history of cryptorchidism. Eighty-five percent of the cases were low risk, 9% were intermediate risk, and 6% were high-risk. The initial treatment modality was orchiectomy plus active surveillance in 15 cases, orchiectomy plus radiotherapy in 19 cases, orchiectomy plus chemotherapy in 65 cases, and chemotherapy followed by orchiectomy in 2 cases. Three-year disease-free survival was 98% in the low-risk group, 87% in the intermediate-risk group, and 66.7% in the high-risk group. Overall 3-year survival was 99% for the low-risk group, 100% for the intermediate-risk group, and 66.7% for the high-risk group (p‹0.0001).
Conclusion: Testicular tumor management should be multidisciplinary and based on the international risk group classification.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics 2016. CA Cancer J Clin. 2016;66(1):7-30.

2. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer statistics 2014. [en línea]. Dirección URL: . [Consulta: 22 de noviembre 2014].

3. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252-71.

4. Scott M, Stevenson, MD. Epidemiology and diagnosis of testis cancer. Urol Clin N Am. 2015;42(3):269-275.

5. Moch H, Humphrey PA, Ulbright TM, et al. Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours. Lyon 2016. Dirección URL: .

6. Bosl GJ, Motzer RJ. Testicular germ-cell cáncer. N Engl J Med. 1997;337(4):242.

7. Jiménez-Ríos MA, Solares-Sánchez ME, Martínez-Cervera PF, et al. Panorama epidemiológico del cáncer genitourinario en la zona centro de México. Rev Mex Urol. 2011;71(Supl 3):36-39.

8. Sedano-Basilio JE, Mayorga-Gómez E, et al. Epidemiología de los tumores genitourinarios en una década. Rev Mex Urol. 2016;76(3):131-140.

9. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.

10. International Germ Cell Consensus Classification: a prognostic factor- based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594-603.

11. Germà-Lluch JR, García-del Muro X, Maroto P, et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumors of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 2002;42(6):553-562.

12. Martín FL, Garrido ML, Álvarez EL, et al. Estudio descriptivo de los tumores testiculares germinales: 13 años de experiencia en el área de Badajoz. Arch Esp Urol 2007;60(5):531-537.